Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) EBT Margin (2021 - 2025)

Krystal Biotech (KRYS) has disclosed EBT Margin for 4 consecutive years, with 47.75% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 560.0% to 47.75% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 48.7% through Dec 2025, up 1587.0% year-over-year, with the annual reading at 48.69% for FY2025, 1587.0% up from the prior year.
  • EBT Margin hit 47.75% in Q4 2025 for Krystal Biotech, down from 49.05% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1059.79% in Q1 2021 to a low of 2.06% in Q1 2024.
  • Historically, EBT Margin has averaged 212.5% across 4 years, with a median of 48.72% in 2025.
  • Biggest five-year swings in EBT Margin: tumbled -90822bps in 2024 and later soared 4738bps in 2025.
  • Year by year, EBT Margin stood at 1059.79% in 2021, then plummeted by -98bps to 25.29% in 2023, then skyrocketed by 111bps to 53.35% in 2024, then decreased by -10bps to 47.75% in 2025.
  • Business Quant data shows EBT Margin for KRYS at 47.75% in Q4 2025, 49.05% in Q3 2025, and 48.72% in Q2 2025.